Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05191472 · OUTCOME

Median Overall Survival (OS) at 12 Months

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies · Source last updated 2025-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

For OS, participants who remain alive at the end of study follow-up will be censored at the time when the participants is known to be alive. Results will be summarized using the Kaplan-Meier method. The 12-months percentage of participants alive, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.

Analysis population: Data not collected

Groups in this outcome

Treatment (Pembrolizumab)

Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Pembrolizumab)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
For OS, participants who remain alive at the end of study follow-up will be censored at the time when the participants is known to be alive. Results will be summarized using the Kaplan-Meier method. The 12-months percentage of participants alive, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.
groups
  1. description
    Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Pembrolizumab)
population Description
Data not collected
reporting Status
POSTED
time Frame
Up to 2 years
title
Median Overall Survival (OS) at 12 Months
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice